ADC Therapeutics Q2 FY26 net loss narrows 70.75% to $16.6 million; revenue rises 2.99% to $19.25 million

Reuters2026/08/13 11:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

ADC Therapeutics posted Q2 GAAP net loss of USD 16.6 million, narrowing from USD 56.6 million a year earlier.
Total revenue rose 2.17% year over year to USD 19.25 million, driven by net product revenue of USD 18.6 million.
Operating loss improved to USD 25.41 million from USD 44.15 million, as total operating expenses fell 29% to USD 44.66 million.
Cash and cash equivalents totaled USD 219.1 million at June 30, 2026; expected cash runway at least into 2028.
FDA raised benefit-risk concerns on LOTIS-5; enrollment completed in LOTIS-7, with Phase 3 planning assessed for ZYNLONTA-glofitamab.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608130730PR_NEWS_USPR_____NY25487) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

ADC Therapeutics Q2 FY26 net loss narrows 70.75% to $16.6 million; revenue rises 2.99% to $19.25 million

You may also like

Crypto prices